Characteristics and specifications of dashboards developed for the COVID-19 pandemic: a scoping review.

Aim: The use of information-based solutions such as dashboards is on the rise for taking fact-based actions against the COVID-19 crisis. This scoping review aimed to comprehensively investigate COVID-19 dashboards from different technical perspectives. Subject and methods: Three main bibliographic databases, PubMed, Web of Science, and Scopus, were searched on 28 August 2021 to retrieve relevant studies. Arksey and O'Malley's (Int J Soc Res Methodol 8(1):19-32, 2005) methodological framework and the enhanced version of this methodology developed by Levac et al. (Implement Sci 5(1):1-9, 2010) were adopted for conducting this review. Results: In total, 26 articles were included. The COVID-19 dashboards mainly focused on the infected (n = 25), deceased (n = 17), and recovered cases (n = 13), as well as the performed test (n = 10). Most of the dashboards were interactive, with public accessibility targeting various user groups. While some dashboards were both informative and supportive (38%), most were mainly informative (92%). The dashboard data were generally analyzed using simple techniques (58%) and delivered through web-based applications (88%). Conclusion: Dashboards can help immediately manage, analyze, and summarize a huge amount of information about a COVID-19 outbreak. The findings revealed that the developed COVID-19 dashboards share more or less analogous characteristics that could lay the groundwork for designing and developing dashboards for any other pandemic.

Ahmed glaucoma valve implantation with and without subconjunctival bevacizumab in refractory glaucoma.

PURPOSE: To evaluate the effects of subconjunctival bevacizumab injection on intraocular pressure (IOP), hypertensive phase, and failure and success rates of Ahmed Glaucoma Valve (AGV) implantation. METHODS: A total of 63 eyes of 63 patients (30 cases in control and 33 cases in bevacizumab group) were included in this randomized masked prospective clinical trial. Pre- and postoperative BCVA, IOP, number of medications, complications and success rates were compared between AGV + bevacizumab and AGV alone group. RESULTS: Both groups showed statistically significant reductions in IOP in all their follow-up visits (P < 0.05). The mean IOP was lower in the AGV + Bevacizumab group than AGV group in all follow-up visits. However, the difference was only significant at the 3rd month (17.3 ± 6.2 vs. 20.7 ± 4.6, p = 0.04). The number of medications was not differed significantly between the two groups at their last visit (p value = 0.84) Complete success rate was higher in AGV + Bevacizumab. However, the difference was not significant (p = 0.73). The qualified and overall success rate, failure rate and the need for second tube were not statistically different between the two groups. The hypertensive phase was not statistically significant between the 2 groups (33.3% in AGV + Bevacizumab group and 50% in AGV group, p = 0.06) CONCLUSION: Adjunctive use of Bevacizumab during AGV implantation is beneficial in controlling hypertensive phase and IOP control and may lead to higher success rates and lower failure rates after AGV implantation. However, whether it's clearly beneficial or its exact role remains to be investigated.

Bupivacaine Injection without Electromyographic Guide for Correction of Residual Esotropia and Exotropia after Strabismus Surgery.

Purpose: To evaluate the effect of bupivacaine injection without electromyographic guide for correcting residual esotropia and exotropia after strabismus surgery. Methods: Thirty patients with residual esotropia or exotropia after strabismus surgery were included in the study. Three milliliters of bupivacaine 0.5% were injected into medial or lateral rectus muscle without electromyographic guide. Results: The mean pre-injection misalignments were 14.8 ± 3.4 (8-20) PD at distance and 14.7 ± 4.4 (6-25) PD at near. The 1 month post-injection alignment changes were 5.2 ± 2.6 (2-13) PD at distance and 6.5 ± 3.1 (2-18) PD at near. The 6 months post-injection alignment changes were 5.8 ± 2.6 (2-13) PD at distance and 7.0 ± 3.6 (2-18) PD at near. LogMAR of the worst eye had strong correlations with 6 months far alignment change (ρ = 0.39, p = .04), 6 months near alignment change (ρ = 0.41, p = .03), and 12 months near alignment change (ρ = 0.69, p = .01). Conclusion: The effect of bupivacaine injection without electromyographic guide for correcting residual esotropia or exotropia after strabismus surgery was between 2 and 18 PD, comparable with other studies on unoperated cases. The effect of bupivacaine may increase with decreasing visual acuity.